Every open market buy and sale of Crescent Biopharma, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net buyers over the last 12 months: $30.6M bought and $1.5M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when CBIO insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an CBIO officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every CBIO insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Jonathan McNeillPresident and COO | Sale plan | 4,570 | $16.90 | $77K | 134,588 | Sep 18Form 4 |
| Sep 18, 2026 | Joshua T BrummCEO | Sale plan | 9,447 | $16.91 | $160K | 271,765 | Sep 18Form 4 |
| Sep 16, 2026 | Barbara Harlin BisphamSee Remarks | Sale plan | 620 | $17.90 | $11K | 18,710 | Sep 18Form 4 |
| Sep 16, 2026 | Richard William ScalzoCFO | Sale plan | 568 | $17.90 | $10K | 19,730 | Sep 18Form 4 |
| Sep 16, 2026 | Ellie Eunkyung ImChief Medical Officer | Sale plan | 623 | $17.90 | $11K | 21,446 | Sep 18Form 4 |
| Sep 16, 2026 | Jan PinkasChief Scientific Officer | Sale plan | 658 | $17.90 | $12K | 21,581 | Sep 18Form 4 |
| Sep 16, 2026 | Ryan LynchSee Remarks | Sale plan | 240 | $17.90 | $4K | 13,631 | Sep 18Form 4 |
| Jul 16, 2026 | Fairmount Funds Management LLCDirector | Buy | 853,450 | $14.50 | $12.4M | 3,601,316 | Jul 20Form 4 |
| Jun 22, 2026 | Joshua T BrummCEO | Sale plan | 42,305 | $17.99 | $761K | 281,212 | Jun 23Form 4 |
| Jun 22, 2026 | Jonathan McNeillPresident and COO | Sale plan | 20,549 | $17.99 | $370K | 139,158 | Jun 23Form 4 |
| Jun 22, 2026 | Ellie Eunkyung ImChief Medical Officer | Sale plan | 1,219 | $17.99 | $22K | 22,069 | Jun 23Form 4 |
| Jun 22, 2026 | Barbara Harlin BisphamSee Remarks | Sale plan | 1,218 | $17.99 | $22K | 19,330 | Jun 23Form 4 |
| Jun 22, 2026 | Richard William ScalzoCFO | Sale plan | 1,112 | $17.99 | $20K | 20,298 | Jun 23Form 4 |
| Jun 22, 2026 | Jan PinkasChief Scientific Officer | Sale plan | 1,288 | $17.99 | $23K | 22,239 | Jun 23Form 4 |
| Jun 22, 2026 | Ryan LynchSee Remarks | Sale plan | 465 | $17.99 | $8K | 13,871 | Jun 23Form 4 |
CBIO insider trading FAQ
Are CBIO insiders buying or selling?
Insiders are net buyers over the last 12 months. 2 insiders bought $30.6M of CBIO on the open market in 2 trades, and 7 sold $1.5M in 14 trades, 100% of that under pre-arranged trading plans.
When did an CBIO insider last buy shares?
Fairmount Funds Management LLC (Director) bought 853,450 shares for $12.4M on Jul 16, 2026, reported on Jul 20, 2026.
When did an CBIO insider last sell shares?
Jonathan McNeill (President and COO) sold 4,570 shares for $77K on Sep 18, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
